Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 8NIH 4INDUSTRY 4NETWORK 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Gynecologic 2NET 1Gastrointestinal 1Endocrine 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Observation 2pembrolizumab 1olaparib 1lenvatinib 1copper dotatate CU-64 1Tomography, Emission-Computed, Single-Photon 1Thyroxine 1Thyroidectomy 1Reverse Transcriptase Polymerase Chain Reaction 1Positron Emission Tomography Computed Tomography 1PM 01183 1Lymph Node Excision 1Lutetium-177 1Irinotecan 1Iodine-124 1Iodine-123 1Injections 1Histocompatibility Testing 1Etoposide 1Cisplatin 1Catecholamines 1Capecitabine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Etoposide × Endocrine × Clear all
NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown
112 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡